Evidence-Based Cardiovascular–Kidney–Metabolic Therapies in Kidney Transplant Recipients
- 24 July 2026
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Abstract
Pivotal clinical trials have heralded several new classes of pharmacologic agents focused on improving combined heart–kidney outcomes among patients with cardiovascular–kidney–metabolic syndrome. This review compiles the current evidence pertaining to the use of these novel, exciting classes of agents among kidney transplant recipients (KTRs). Treatment with renin–angiotensin–aldosterone system inhibitors continues to remain the backbone of pharmacologic management among KTRs for several indications. Data from systematic reviews and meta-analyses support the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists with several comorbidities. However, evidence for both nonsteroidal and steroidal mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors is emerging and not adequate to support routine clinical use in KTRs. Finally, data from randomized controlled trials on statins serve as a reminder of their impact in the metabolic milieu following kidney transplantation. Using the recently introduced paradigm of cardiovascular–kidney–metabolic syndrome, this review proposes that four pharmacologic agents constitute the key pillars for improving downstream heart–kidney outcomes on the basis of existing evidence: renin–angiotensin–aldosterone system inhibitors, statins, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists. Furthermore, this review highlights relevant practical drug interactions with immunosuppressants and considerations of tolerability of these agents among KTRs. Finally, this review discusses specific management considerations for coronary heart disease, heart failure, and atrial fibrillation with unique nuances applicable to KTRs. There remains a critical need for randomized trials in this vulnerable population focused on improvement in combined heart–kidney outcomes.Keywords
Funding Information
- Mid-America Transplant (Jane A. Beckman Endowed Chair)
- American Heart Association (Career Development Award 24CDA1277194)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK120551, R01 DK137111-01, R01DK139339)
This publication has 94 references indexed in Scilit:
- Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in ManagementCardiology and Therapy, 2026
- SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and AlbuminuriaJAMA, 2026
- GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney eventsJournal of Diabetes & Metabolic Disorders, 2026
- Safety and efficacy of atrial fibrillation ablation in kidney transplant patientsJournal of Interventional Cardiac Electrophysiology, 2025
- Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitusDiabetes & Metabolism, 2025
- Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitusDiabetes & Metabolism, 2025
- Recipient race modifies the association between obesity and long-term graft outcomes after kidney transplantationAmerican Journal of Transplantation, 2023
- Comparison of the Frequency of Acute Kidney Injury in Patients With Renal Transplant Who Underwent Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft SurgeryThe American Journal of Cardiology, 2017
- Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant RecipientsJAMA Cardiology, 2017
- Renal failure and acute myocardial infarction: Clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial InfarctionAmerican Heart Journal, 2012